Year To Quarter End Consolidated Statement Of Income

Oncolys BioPharma Inc. - Filing #7339370

Concept 2024-01-01 to
2024-03-31
2023-01-01 to
2023-03-31
Year to quarter end consolidated statement of income
Statement of income
Net sales
JPY
35,000,000 JPY
Cost of sales
JPY
32,433,000 JPY
Gross profit (loss)
JPY
2,566,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
378,872,000 JPY
328,145,000 JPY
Operating profit (loss)
-378,872,000 JPY
-325,578,000 JPY
Non-operating income
Interest income
518,000 JPY
149,000 JPY
Non-operating income
19,187,000 JPY
3,341,000 JPY
Non-operating expenses
Interest expenses
1,140,000 JPY
855,000 JPY
Non-operating expenses
3,607,000 JPY
855,000 JPY
Ordinary profit (loss)
-363,292,000 JPY
-323,092,000 JPY
Extraordinary income
Gain on sale of non-current assets
JPY
136,000 JPY
Extraordinary income
JPY
136,000 JPY
Profit (loss) before income taxes
-363,292,000 JPY
-322,955,000 JPY
Income taxes - current
940,000 JPY
736,000 JPY
Income taxes
940,000 JPY
736,000 JPY
Profit (loss)
-364,233,000 JPY
-323,691,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.